Randomized Comparison of Everolimus-Eluting Stents and Sirolimus-Eluting Stents in Patients With ST Elevation Myocardial Infarction RACES-MI Trial by Di Lorenzo, Emilio et al.
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 7 , N O . 8 , 2 0 1 4
ª 2 0 1 4 B Y T H E A M E R I C A N CO L L E G E O F C A R D I O L O G Y F O U N D A T I O N I S S N 1 9 3 6 - 8 7 9 8 / $ 3 6 . 0 0
P U B L I S H E D B Y E L S E V I E R I N C . h t t p : / / d x . d o i . o r g / 1 0 . 1 0 1 6 / j . j c i n . 2 0 1 4 . 0 2 . 0 1 6Randomized Comparison of Everolimus-
Eluting Stents and Sirolimus-Eluting Stents
in Patients With ST Elevation Myocardial
Infarction
RACES-MI TrialEmilio Di Lorenzo, MD, PHD,* Rosario Sauro, MD,* Attilio Varricchio, MD, PHD,* Michele Capasso, MD,*
Tonino Lanzillo, MD,* Fiore Manganelli, MD,* Giannignazio Carbone, MD,* Francesca Lanni, MD,*
Maria Rosaria Pagliuca, MD,* Giovanni Stanco, MD,* Giuseppe Rosato, MD,* Harry Suryapranata, MD, PHD,y




MaOBJECTIVES The aim of the current study was to compare everolimus-eluting stents (EES) with sirolimus-eluting
stents (SES) in patients undergoing primary angioplasty.
BACKGROUND Drug-eluting stents may offer beneﬁts in terms of repeat revascularization. However, as shown for
ﬁrst-generation drug-eluting stents, they may be counterbalanced by a potential higher risk of stent thrombosis,
especially among patients with ST-segment elevation myocardial infarction (STEMI). No data have been reported so far
on the long-term beneﬁts and safety of the new generation of drug-eluting stents in STEMI.
METHODS Consecutive STEMI patients admitted within 12 h of symptom onset and undergoing primary angioplasty and
stent implantation at a tertiary center with 24-h primary percutaneous coronary intervention capability were randomly
assigned to SES or EES. The primary endpoint was a major adverse cardiac event at 3-year follow-up. The secondary
endpoints were death, reinfarction, deﬁnite or probable stent thrombosis, and target vessel revascularization at 3-year
follow-up. No patient was lost to follow-up.
RESULTS From April 2007 to May 2009, 500 patients with STEMI were randomized to EES (n ¼ 250) or SES (n¼ 250). No
difference was observed in terms of baseline demographic and clinical characteristics between the groups. No difference was
observed between the groups in terms of number of implanted stents per patient or total stent length. However, a larger
referencediameterwasobservedwithSES (3.350.51mmvs. 3.250.51mm,p¼0.001),whereaspatients randomizedtoEES
more often received glycoprotein IIb/IIIa inhibitors (54.4%vs. 42.4%, p¼ 0.006). Follow-up data were available in all patients
(1,095 159days).NosigniﬁcantdifferencewasobservedbetweenEESandSES inmajoradversecardiacevents (16%vs.20.8%,
adjustedhazard ratio [HR]:0.75 [95%conﬁdence interval (CI):0.5 to 1.13], p¼0.17), cardiacdeath (4.4%vs. 5.6%, adjustedHR:
0.77 [95%CI:0.35 to 1.71], p¼0.53), recurrentMI (6.4%vs. 10%,adjustedHR:0.62 [95%CI:0.33 to 1.16], p¼0.13), and target
vessel revascularization (4.8%vs.4.8%, adjustedHR: 1.00 [95%CI:0.45 to 2.32], p¼0.99).However, EESwas associatedwith
a signiﬁcant reduction in stent thrombosis (1.6% vs. 5.2%, adjusted HR: 0.3 [95% CI: 0.1 to 0.92], p ¼ 0.035).
CONCLUSIONS This study shows that among STEMI patients undergoing primary angioplasty, EES has similar efﬁcacy
as SES, but is associated with a signiﬁcant reduction in stent thrombosis. (Randomized Comparison of Everolimus Eluting
Stents and Sirolimus Eluting Stent in Patients With ST Elevation Myocardial Infarction [RACES-MI]; NCT01684982)
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ABBR EV I A T I ON S
AND ACRONYMS
BMS = bare-metal stent(s)
CI = conﬁdence interval
DES = drug-eluting stent(s)
EES = everolimus-eluting
stent(s)
HR = hazard ratio
MACE = major adverse cardiac
events




ST = stent thrombosis
STEMI = ST-segment elevation
myocardial infarction
TIMI = Thrombolysis In
Myocardial Infarction
TVR = target vessel
revascularization
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850S everal randomized trials have clearlyshown the adjunctive beneﬁts in termsof mortality from primary percuta-
neous coronary intervention (PCI) as
compared with thrombolysis as reperfusion
strategy in the treatment of patients with
ST-segment elevation myocardial infarction
(STEMI) (1,2). Even though stent implanta-
tion, compared with balloon angioplasty,
has reduced the occurrence of restenosis in
selected STEMI patients (3,4), the outcome
of bare-metal stents (BMS) seem to be worse
in unselected patients with a rate of target
vessel revascularization (TVR) up to 20%
(5,6). Several randomized trials have shown
that drug-eluting stents (DES), compared
with BMS, are associated with a signiﬁcant
reduction in restenosis and TVR in STEMI
patients (7–17). However, concerns have
emerged on the higher risk of stent throm-
bosis (ST) with ﬁrst-generation DES (18).TABLE 1 Baseline Demographic and Clinical Characteristics
of the 2 Groups of Patients
SES (n ¼ 250) EES (n ¼ 250) p Value
Age, yrs 59  12 59  11 0.53
Male 62 67.6 0.19The new-generation DES with more biocompatible
polymers may potentially provide beneﬁts in both
TVR and ST in the setting of STEMI (19). Therefore,
the aim of the RACES-MI (Randomized Comparison
of Everolimus Eluting Stents and Sirolimus Eluting
Stent in Patients With ST Elevation Myocardial Infarc-
tion) trial was to compare everolimus-eluting stents
(EES) with sirolimus-eluting stents (SES) in patients
undergoing primary angioplasty for STEMI at short-
and long-term follow-up.Hypertension 41.2 42 0.86
Diabetes 27.2 25.6
IDDM 9.6 10 0.69
NIDDM 17.6 15.6
Smoking 34.4 33.6 0.85
Previous MI 12 14.4 0.43
Previous CABG 8 6.8 0.61
Previous PCI 12.4 9.6 0.32
Previous CVA 3.2 4 0.63
Family history of CAD 32.4 36 0.4
PAD 2.4 3.2 0.59
Chronic renal failure 8.4 10.4 0.45
Anemia 10.4 8.8 0.54
Heart rate at presentation,
beats/min
65  24 69  24 0.25
Killip class >1 14.4 15.2 0.80
Anterior MI 45.2 42.4 0.53
Ejection fraction, % 47.4  8.4 47.5  8 0.9
Ischemia time, min 177  148 182  152 0.67
Door-to-balloon time, min 44  17 46  16 0.16
Values are mean  SD or percentages.
CABG ¼ coronary artery bypass graft; CAD ¼ coronary artery disease; CVA ¼
cerebrovascular accident; EES ¼ everolimus-eluting stent(s); IDDM ¼ insulin-
dependent diabetes mellitus; MI ¼ myocardial infarction; NIDDM ¼ non–insulin-
dependent diabetes mellitus; PAD ¼ peripheral artery disease; PCI ¼ percutaneous
coronary intervention; SES ¼ sirolimus-eluting stent(s).METHODS
The RACES-MI trial is a prospective, single-center,
randomized trial evaluating the beneﬁts of EES
versus SES implantation in patients undergoing pri-
mary angioplasty for acute STEMI. Individuals
eligible for enrollment were consecutive patients
presenting with STEMI who fulﬁlled all of the
following inclusion criteria: 1) chest pain for more
than 30 min; and 2) ST-segment elevation of $1 mm
in $2 contiguous electrocardiograph leads or with
presumably new left bundle branch block. Exclusion
criteria included the following: 1) active internal
bleeding or a history of bleeding diathesis within the
previous 30 days; 2) contraindication to dual anti-
platelet therapy for 12 months; 3) known allergy to
sirolimus or everolimus; 4) a history of stroke within
30 days or any history of hemorrhagic stroke; 5) his-
tory, symptoms, or ﬁndings suggestive of aortic
dissection; 6) pregnancy; 7) participation in other
trials. No angiographic exclusion criteria were used.The institutional review board of the Ospedale
“S.G. Moscati” (Avellino, Italy) approved the protocol
in 2007, and all patients gave written informed
consent.
Open-label randomization was performed in the
catheterization laboratory after initial angiography by
the treating physician when eligibility criteria were
met. A 1:1 computer-generated random sequence,
without blocking or stratiﬁcation, was used. Sealed
envelopes indicated the treatment group to which the
patients were assigned: SES or EES.
MEDICATIONS. All patients received a 70 U/kg intra-
venous bolus of unfractionated heparin, aspirin
intravenously (500 mg), and clopidogrel (600-mg
loading dose). Glycoprotein IIb/IIIa inhibitor admin-
istration, and the number and length of stents to be
implanted were left to the operator’s discretion. Post-
interventional antiplatelet therapy for all patients
consisted of aspirin (100 mg/day) indeﬁnitely and
clopidogrel (75 mg daily recommended for 12 months).
ANGIOPLASTY PROCEDURE. Stenting procedures
were performed according to standard techniques.
The number and length of stents to be implanted were
TABLE 3 Medical Therapy of the 2 Groups of Patients at
Discharge and Clopidogrel Therapy at Follow-Up
SES (n ¼ 250) EES (n ¼ 250) p Value
Aspirin 100 100 1.0
Beta-blockers 96 92.8 0.12
ACE inhibitors 90.4 91.2 0.76
Statins 99.6 100 0.5
Clopidogrel 100 100 1.0
Clopidogrel at 6 months 98.0 98.8 0.89
Clopidogrel at 12 months 96.0 96.4 0.9
Values are percentages.
ACE ¼ angiotensin-converting enzyme; other abbreviations as in Table 1.
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 7 , N O . 8 , 2 0 1 4 Di Lorenzo et al.
A U G U S T 2 0 1 4 : 8 4 9 – 5 6 EES vs. SES in Primary Angioplasty
851left to the operator’s discretion. The operator was
allowed to implant DES to cover the entire length of
the lesion with coverage of the entire stented segment
and of 5-mm proximal and distal segments. The use of
intravascular ultrasound, adjunctive thrombectomy
devices, distal protection devices, and intra-aortic
balloon pump were left to the operator’s discretion.
ANGIOGRAPHIC ANALYSIS. TIMI (Thrombolysis In
Myocardial Infarction) ﬂow grade 3 coronary ﬂow in
the treated vessel and a residual stenosis <30% were
the criteria used to deﬁne a successful PCI. Quanti-
tative angiographic analyses (Integris Allura, Philips,
Amsterdam, the Netherlands) were performed online
and off-line by 2 experienced technicians who were
unaware of treatment assignment. The average value
was ﬁnally considered for each measured parameter.
DATA COLLECTION AND FOLLOW-UP. As per proto-
col, patients were reviewed at our outpatient clinic or
by telephone interview at 6, 12, 24, and 36 months
after stent implantation. For patients who died dur-
ing follow-up, hospital records and necropsy dataTABLE 2 Angiographic and Procedural Characteristics
of the 2 Groups of Patients

















2 39.2 34.1 0.48
3 10.4 12.0
RD, mm 3.35  0.51 3.25  0.51 0.001
Stent diameter, mm 3.16  0.39 3.09  0.45 0.071
Total stent length, mm 22.0  7.7 22.3  8.0 0.72
Stents, n 1.12  0.35 1.11  0.35 0.8
GP IIb/IIIa inhibitors 42.4 54.4 0.006
Thrombectomy devices 23.2 21.2 0.59
Values are % or mean  SD.
GP ¼ glycoprotein; IRA[ infarct-related artery; LAD ¼ left anterior descending
artery; LCX ¼ left circumﬂex artery; LM ¼ left main artery; RCA ¼ right coronary
artery; RD ¼ reference diameter; SVG ¼ saphenous vein graft; TIMI ¼ Throm-
bolysis In Myocardial Infarction.were reviewed, when possible. No patient was lost to
follow-up.
STUDY ENDPOINTS AND DEFINITIONS. The primary
endpoint was major adverse cardiac events (MACE) at
3-year follow-up, deﬁned as combined cardiac death,
reinfarction, deﬁnite or probable ST, and TVR. Sec-
ondary endpoints were cumulative occurrence of the
following: 1) cardiac death; 2) reinfarction; 3) deﬁnite
or probable ST; and 4) TVR at 3-year follow-up. All
deaths were considered cardiac unless an unequivo-
cal noncardiac cause could be identiﬁed. Recurrent
MI was deﬁned as recurrence of angina symptoms
with typical electrocardiographic changes and in-
crease above the upper limit of normal of creatine
kinase–myocardial band or troponin. The indicationFIGURE 1 MACE in SES Versus EES
Kaplan-Meier curves showing the occurrence of major adverse cardiac





FIGURE 2 Cardiac Death in SES Versus EES
Kaplan-Meier curves showing the occurrence of cardiac death in SES versus
EES. Abbreviations as in Figure 1.
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852for a second intervention had to be substantiated by
symptoms or by electrocardiographic or scintigraphic
evidence of ischemia at rest or during exercise. Sub-
sequent revascularization of other coronary arteries
did not constitute an endpoint. All events were
reviewed by 2 cardiologists blinded to treatment
assignment.
STATISTICAL ANALYSIS. Continuous data were
expressed as mean  SD and categorical data as per-
centages. The analysis of variance was appropriately3 Reinfarction in SES Versus EES
Meier curves showing the occurrence of reinfarction in SES versus EES.
ations as in Figure 1.used for continuous variables. The chi-square test or
the Fisher exact test was used for categorical vari-
ables. The difference in event rates between groups
during the follow-up period was assessed by the
Kaplan-Meier method with the log-rank test.
Furthermore, Cox regression analysis was performed
to correct the results from any difference in baseline
demographic, clinical, angiographic, or procedural
characteristics that were different between the 2
groups. A probability value of p < 0.05 was consid-
ered signiﬁcant.
Sample s ize ca lcu lat ion . According to our previous
reports (4,5), we estimated a rate of target vessel
failure at 3 years of 20% in the SES. With an antici-
pated 2-sided test for differences in independent
binomial proportions at the 5% signiﬁcance level, with
a power of 80%, 220 patients per group were required
to detect a reduction in a primary endpoint of 50%
(from 20% to 10%) with EES versus SES. The number
of patients was extended to 250 per group. Data were
analyzed according to intention-to-treat analysis.
Statistical analysis was performed using SPSS version
17.0 (SPSS, Inc., IBM, Armonk, New York).RESULTS
PATIENT CHARACTERISTICS AND PROCEDURAL
RESULTS. From April 2007 to May 2009, 563
consecutive STEMI patients were assessed for eligi-
bility, and 63 patients were excluded because of
exclusion criteria and/or refusal to participate.
Therefore, our ﬁnal population is represented by
500 STEMI patients who were randomized to EES
(n ¼ 250) or SES (n ¼ 250). As reported in Tables 1
and 2, no difference was observed in terms of base-
line demographic, clinical, and angiographic charac-
teristics between the groups. No difference was
observed between the groups in terms of number of
implanted stents per patient (1.12  0.35 vs. 1.11 
0.35, p ¼ 0.8). As shown in Table 2, no difference was
observed in terms of angiographic and procedural
characteristics. Almost 50% of patients underwent
PCI of the left anterior descending artery. Glycopro-
tein IIb/IIIa inhibitors were more often administered
among patients randomized to EES. Procedural suc-
cess was obtained in 93% to 95% of patients. No
difference was observed in medical therapy at dis-
charge (Table 3).
CLINICAL OUTCOME AT FOLLOW-UP. Follow-up
data were available in all patients (1,095  159 days).
No difference was observed in terms of duration of
dual antiplatelet therapy between the 2 groups
(Table 3).
TABLE 4 Timing of ST According to ARC Deﬁnition of Deﬁnite,
Probable, and Possible
SES (n ¼ 250) EES (n ¼ 250) p Value
Acute deﬁnite 0 0 1.0
Acute probable 0 0 1.0
FIGURE 4 ST in SES Versus EES
Kaplan-Meier curves showing the occurrence of stent thrombosis (ST)
in SES versus EES. Abbreviations as in Figure 1.
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853PRIMARY STUDY ENDPOINT. Major adverse cardiac
events (MACE). MACE were observed in a total of 92
patients (18.4%). As shown in Figure 1, no signiﬁcant
difference was observed between EES and SES (16%
vs. 20.8%, hazard ratio [HR]: 0.75 [95% conﬁdence
interval (CI): 0.5 to 1.13], p ¼ 0.17; adjusted HR: 0.73
[95% CI: 0.48 to 1.10], p ¼ 0.13).
SECONDARY STUDY ENDPOINTS. Card iac morta l i ty .
A total of 28 patients had died at follow-up. Cardiac
death was observed in 25 patients. As shown in
Figure 2, no difference was observed in cardiac death
between EES and SES (4.4% vs. 5.6%, HR: 0.77 [95%
CI: 0.35 to 1.71], p ¼ 0.53; adjusted HR: 0.75 [95% CI:
0.34 to 1.67], p ¼ 0.48).
Repeat MI . Recurrent MI was observed in 41 patients
(8.2%). As shown in Figure 3, no difference was
observed between EES and SES (6.4% vs. 10%, HR:
0.62 [95% CI: 0.33 to 1.16], p ¼ 0.13; adjusted HR: 0.57
[95% CI: 0.3 to 1.07], p ¼ 0.08). Similar rates of rein-
farction were observed after the exclusion of cases of
deﬁnite or probable ST (adjusted HR: 0.92 [95% CI:
0.42 to 2.01], p ¼ 0.84).
Stent thrombos is . ST was observed in 17 patients
(3.4%). As shown in Figure 4, EES was associated with
a signiﬁcant reduction in ST (1.6% vs. 5.2%, HR: 0.3
[95% CI: 0.1 to 0.92], p ¼ 0.035; adjusted HR: 0.26
[95% CI: 0.08 to 0.80], p ¼ 0.019). None of the ST
events was related to premature discontinuation
during the ﬁrst year of follow-up, whereas in case of
very late ST, no patient was on dual antiplatelet
therapy because it was stopped at 1 year after primary
PCI. Time distribution of all types of ST events is
shown in Table 4. Landmark analysis showed beneﬁts
with EES within and later than 1-year follow-up as
compared to beneﬁts associated with SES (Fig. 5).
Target-vessel revascularization. TVR was observed in
24 patients (4.8%). As reported in Figure 6, no dif-
ference was observed in terms of TVR between EES
and SES (4.8% vs. 4.8%, HR: 1 [95% CI: 0.45 to 2.32],
p ¼ 0.99; adjusted HR: 1.0 [95% CI: 0.44 to 2.25], p ¼
0.99).Acute possible 0 0 1.0
Subacute deﬁnite 4 (1.6) 1 (0.4) 0.22
Subacute probable 0 0 1.0
Subacute possible 0 0 1.0
Late deﬁnite 4 (1.6) 1 (0.4) 0.17
Late probable 1 (0.4) 1 (0.4) 1.0
Late possible 0 0 1.0
Very late deﬁnite 3 (1.2) 0 0.089
Very late probable 2 (0.8) 1 (0.4) 0.54
Very late possible 0 0 0
Values are n (%).
ARC ¼ Academic Research Consortium; ST ¼ stent thrombosis; other abbrevi-
ations as in Table 1.DISCUSSION
This is among the ﬁrst randomized studies comparing
EES and SES in patients undergoing primary angio-
plasty for STEMI. The main ﬁnding of the current
study is that at 3-year follow-up, EES and SES are
equally effective, whereas EES, as compared to SES, is
associated with a signiﬁcant reduction in deﬁnite/
probable ST. After initial safety concerns, numerous
studies and randomized trials have demonstrated the
safety and efﬁcacy of stenting in the setting of STEMI(3,5,6). A recent comprehensive meta-analysis in
patients undergoing primary PCI has shown the ben-
eﬁts of stenting versus balloon angioplasty alone in
terms of reducing TVR, although no deﬁnite impact
on death and reinfarction was present (4). However,
restenosis rates after BMS in STEMI patients are still
high, especially in unselected patients with complex
lesion morphology (5,6). Many randomized trials
have been conducted, therefore, on the use of DES
(7–17). However, recent concerns have emerged
regarding the risk of late ST and death associated with
DES. As most episodes of ST result in MI, this increase
FIGURE 5 ST Within or Later Than 1-Year Follow-Up in SES Versus EES
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854with DES may affect mortality, particularly after
primary angioplasty, as reinfarction is a major deter-
minant of survival (20,21). In fact, a recent individual-
patient data meta-analysis including >6,000 patients
has shown that ﬁrst-generation DES, as compared
with BMS, are associated with a signiﬁcant reduction
in TVR, but higher rates of late ST (18). Therefore,
the attention of research has been focused on new
DES technologies with more biocompatible or bio-
absorbable polymers. Among elective patients, those6 TVR in SES Versus EES
Meier curves showing the occurrence of target vessel revasculariza-
R) in SES versus EES. Abbreviations as in Figure 1.stents have been shown to further improve outcome
as compared with the outcomes of BMS and ﬁrst-
generation DES (19). Few studies have so far investi-
gated the new generation of DES in the setting of
STEMI.
The CONFORTABLE-AMI (Comparison of Biolimus
Eluted From an Erodible Stent Coating With Bare
Metal Stents in Acute ST-Elevation Myocardial
Infarction) trial (22) compared a biolimus-eluting
stent with biodegradable polymer versus BMS in
1,500 patents. At 1-year follow-up, MACE occurred in
24 patients (4.3%) receiving biolimus-eluting stents
and 49 patients (8.7%) receiving BMS (p ¼ 0.004). The
difference was driven by a lower risk of target vessel-
related reinfarction (0.5% vs. 2.7%, p ¼ 0.01) and
ischemia-driven target lesion revascularization (1.6%
vs. 5.7%, p < 0.001) in patients receiving biolimus-
eluting stents versus BMS.
In the EXAMINATION (Clinical Evaluation of
Xience-V Stent in Acute Myocardial Infarction) trial
(23), 1,498 STEMI patients were randomly assigned to
receive EES or BMS. At 1-year follow-up, the primary
endpoint (patient-oriented combined endpoint of all-
cause death, any recurrent MI, and any coronary
revascularization) was similar in both groups (11.9% in
the EES group vs. 14.2% in the BMS group; p ¼ 0.19).
However, EES was associated with signiﬁcantly lower
rates of target lesion and vessel revascularization (2.1%
vs. 5.0%, p¼ 0.003, and 3.7% vs. 6.8%, p ¼ 0.0077) and
ST (0.5% vs. 1.9% for deﬁnite and 0.9% vs. 2.5% for
combined deﬁnite or probable, both p ¼ 0.019).
In the XAMI (XienceV Stent vs Cypher Stent in
Primary PCI for Acute Myocardial Infarction) (24)
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855trial, 625 patients with acute MI were randomized
(2:1) to receive EES or SES. The primary endpoint was
MACE at 1 year consisting of cardiac death, nonfatal
acute MI, or any TVR. EES was associated with a sig-
niﬁcant reduction in the primary endpoint (4% vs.
7.7%, p ¼ 0.048), whereas no difference was observed
in terms of cardiac mortality (1.5% vs. 2.7%, p ¼ 0.36),
and deﬁnite and/or probable ST (1.2% vs. 2.7%,
p ¼ 0.21).
This is the ﬁrst study comparing EES and SES in
STEMI with available 3-year follow-up data. Whereas
EES and SES performed equally in terms of efﬁcacy
(similar TVR rates), EES was associated with a sig-
niﬁcant reduction in ST.
Together, these data support the preserved efﬁ-
cacy but improved safety of new-generation as
compared to ﬁrst-generation DES in the setting of
STEMI.
STUDY LIMITATIONS. Despite long-term follow-up
data, due to the relatively small sample size, the study
is underpowered to evaluate mortality and othersecondary endpoints. Furthermore, a larger use of
thrombectomy devices, by reducing the thrombotic
burden, might have potentially affected the results of
our study (25).CONCLUSIONS
This study shows that among STEMI patients under-
going primary angioplasty, at 3-year follow-up EES
and SES are equally effective, whereas EES is associ-
ated with a signiﬁcant reduction in deﬁnite/probable
ST. Therefore, while waiting for the results of addi-
tional large studies with long-term follow-up data,
EES may be safely considered for use in STEMI pa-
tients undergoing primary angioplasty.
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